{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bendamustine+HCL&page=2", "query": { "intervention": "Bendamustine HCL", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Bendamustine+HCL&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-20T17:50:58.545Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03039114", "title": "Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" }, { "name": "Hexal", "type": "DRUG" }, { "name": "Gazyvaro", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2017-02-15", "completion_date": "2021-03-30", "has_results": false, "last_update_posted_date": "2025-08-21", "last_synced_at": "2026-09-20T17:50:58.545Z", "location_count": 6, "location_summary": "Gilbert, Arizona • La Jolla, California • Fairway, Kansas + 3 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03039114" }, { "nct_id": "NCT04629729", "title": "FT819 in Subjects With B-cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, B-Cell", "Chronic Lymphocytic Leukemia", "Precursor B-Cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "FT819", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-07-12", "completion_date": "2039-09-30", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-09-20T17:50:58.545Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Davis, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Davis", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04629729" }, { "nct_id": "NCT00899431", "title": "Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 39, "start_date": "2009-05-06", "completion_date": "2018-10-07", "has_results": true, "last_update_posted_date": "2020-01-27", "last_synced_at": "2026-09-20T17:50:58.545Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899431" }, { "nct_id": "NCT04217317", "title": "CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed T-Cell Lymphoma", "Refractory T-Cell Lymphoma", "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "CPI 613", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-09-16", "completion_date": "2024-07-11", "has_results": true, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-09-20T17:50:58.545Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04217317" }, { "nct_id": "NCT04745832", "title": "Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma (FL)", "Non Hodgkin Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Zandelisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "CHOP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MEI Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2021-08-13", "completion_date": "2023-03-20", "has_results": true, "last_update_posted_date": "2024-11-04", "last_synced_at": "2026-09-20T17:50:58.545Z", "location_count": 14, "location_summary": "Tucson, Arizona • Fountain Valley, California • Long Beach, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04745832" }, { "nct_id": "NCT05451771", "title": "Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AL Amyloidosis" ], "interventions": [ { "name": "Venetoclax Oral Tablet, 200 mg", "type": "DRUG" }, { "name": "FISH assay", "type": "DEVICE" }, { "name": "Venetoclax Oral Tablet, 400 mg", "type": "DRUG" }, { "name": "Dexamethasone Oral, 10 mg", "type": "DRUG" }, { "name": "Dexamethasone Oral, 20 mg", "type": "DRUG" }, { "name": "Daratumumab Injection", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Venetoclax MTD with Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2022-10-26", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-20T17:50:58.545Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05451771" }, { "nct_id": "NCT00790855", "title": "Bendamustine in Acute Leukemia and MDS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 27, "start_date": "2008-11", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2012-12-04", "last_synced_at": "2026-09-20T17:50:58.545Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00790855" }, { "nct_id": "NCT04115631", "title": "A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 360, "start_date": "2019-12-13", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-20T17:50:58.545Z", "location_count": 504, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 358 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04115631" }, { "nct_id": "NCT01222260", "title": "Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AL Amyloidosis" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2013-01", "completion_date": "2019-07-03", "has_results": true, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-09-20T17:50:58.545Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222260" }, { "nct_id": "NCT03872180", "title": "Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CCND1 Positive", "Mantle Cell Lymphoma", "t(11;14) Positive" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2019-04-11", "completion_date": "2026-07-15", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-20T17:50:58.545Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Johns Creek, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Johns Creek", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03872180" } ] }